Galecto (GLTO)
(Delayed Data from NSDQ)
$0.55 USD
+0.03 (5.80%)
Updated Jul 12, 2024 03:58 PM ET
After-Market: $0.54 -0.01 (-0.92%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GLTO 0.55 +0.03(5.80%)
Will GLTO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GLTO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GLTO
Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?
New Strong Buy Stocks for February 14th
GLTO: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock
Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More
Galecto (GLTO) Down 71% as Lung Disease Candidate Fails
Other News for GLTO
Analysts’ Top Healthcare Picks: Sagimet Biosciences, Inc. Class A (SGMT), Galecto (GLTO)
Galecto price target lowered by $1 at Oppenheimer, here's why
GLTO Stock Earnings: Galecto Beats EPS for Q1 2024
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
Galecto enrolls first patient in GB1211 trial